PRNewsWire
10 Jun 2026, 06:19 UTC · 3h ago
Lundbeck to present new patient data on neuroendocrine and neuroimmunology programs at ENDO 2026
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
PRNewsWire
10 Jun 2026, 06:19 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Lundbeck will present preliminary Phase II data for asedebart in patients with Cushing's disease (CD) at the ENDO 2026 conference. — Phase II data is a critical inflection point for biotech valuations, as it provides the first signal of clinical efficacy for a potential new revenue stream.
+0.50Lundbeck will share preclinical and Phase Ib exploratory findings for Lu AG22515 in patients with Thyroid Eye Disease (TED). — Early-stage data on CD40L pathway modulation expands the company's pipeline potential, though the impact is lower than Phase II results.
+0.30Asedebart has received Orphan Drug Designation (ODD) in the US, EU, and Japan for Cushing's disease and congenital adrenal hyperplasia. — ODD provides regulatory incentives and exclusivity benefits that increase the potential commercial value of the drug upon approval.
+0.20Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The company is presenting promising Phase II and Phase Ib data for its neuroendocrine and neuroimmunology pipeline, indicating progress in rare disease programs.
Go deeper
You just saw which tickers this one story hits. A free account turns that into a standing screen: the movers delivered on schedule, before the chart catches up.
On this page · free
In the platform
Free account, 30 seconds. No credit card. Covers all 10 tickers this story moves.
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Screener bridge
Catch the names this kind of story moves — before the chart does.
Get the full NIS Momentum results every Friday at 4PM ET — free via email or Telegram.
Seeking Alpha
4h ago
